Two Avalo Therapeutics directors to not stand for re-election at 2026 Annual Meeting

Avalo Therapeutics, Inc.

Dr. Jonathan Goldman and Mitchell Chan will not stand for re-election to the Board at the 2026 Annual Meeting.
They will continue to serve as board members until the 2026 Annual Meeting.
Decisions are not due to any disagreement with the Company regarding operations, policies, or practices.
The Board expressed gratitude for their service and contributions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Jonathan Goldman

Director

AVTX · Avalo Therapeutics, Inc.

Filed: Mar 27, 2026 23:59 UTC

On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”), each notified the Company of his decision to not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders

Departed

Mitchell Chan

Director

AVTX · Avalo Therapeutics, Inc.

Filed: Mar 27, 2026 23:59 UTC

On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”), each notified the Company of his decision to not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders

Source: SEC EDGAR

accession 0001534120-26-000016

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.